Weight-loss injections built on GLP-1 and dual GIP/GLP-1 agonists — branded as Wegovy and Mounjaro — have become the most discussed new tool in the obesity and metabolic health field. But NHS access to them is not a simple prescription request. It runs on a published ladder of BMI thresholds and weight-related conditions, delivered through two different NHS routes with very different waiting times. Understanding that ladder matters for anyone trying to work out where they, or the population a screening programme serves, actually sit.
Two Numbers That Decide Access: BMI and Comorbidity Count
NHS eligibility for these medicines is not judged on BMI alone. It is judged on BMI combined with a count of weight-related conditions from a fixed list: high blood pressure, type 2 diabetes, vascular or heart disease, obstructive sleep apnoea, and high cholesterol. In the first phase of GP-practice prescribing, the bar was set deliberately high: a BMI of 40 or more — or 37.5 or more for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, who carry higher health risk at a lower BMI — together with at least four of those five conditions. That combination defines what NHS England has described as “highest clinical need,” and it is why the earliest wave of patients prescribed Mounjaro through a GP practice were, almost without exception, people already managing several other long-term conditions at once.
Applicants must also be adults, and are expected to have already tried structured diet and activity changes without sustained results before injections become an option. The medicine is a tool layered on top of the prevention agenda’s existing behavioural and dietary work, not a substitute for it.
Why Eligibility Is Widening in Stages, Not All at Once
The BMI-and-comorbidity bar is not fixed. It is designed to loosen in scheduled steps as capacity in general practice grows. The published trajectory broadens the qualifying group to a BMI of 35 or more with four of the five conditions, and later to a BMI of 40 or more with only three conditions. Each step brings a materially larger patient population into scope, which is precisely why the criteria are staged rather than opened all at once: primary care capacity, medicine supply, and the wraparound support services described below all have to expand in step with demand, not after it.
For a London population, the practical effect is that two people with an identical BMI can have very different NHS eligibility today, depending on how many of the five listed conditions they already carry — and that gap narrows, but does not disappear, at each stage of the rollout.
Two NHS Routes, Two Different Waits
There are two distinct ways to reach a GLP-1 medicine on the NHS, and they are not interchangeable.
| Route | How it works | Typical experience |
|---|---|---|
| Specialist Weight Management (Tier 3) service | GP referral into a dedicated multidisciplinary clinic; covers the widest NICE-approved group, including Wegovy | Long waits are common, sometimes months, and not every area commissions the same level of service |
| Direct GP-practice prescribing | Mounjaro prescribed within the practice itself, for patients meeting the current highest-need threshold | Faster in principle, but practice participation is voluntary and locally funded, so availability varies by area |
Because practice-level participation is optional and funded locally, two patients who meet identical clinical criteria can face different realities simply because of which practice, and which area’s commissioning decisions, they fall under. That local variability sits alongside — but is distinct from — the clinical eligibility ladder itself.
What “Wraparound Care” Actually Means
NHS prescribing of these medicines is not meant to be a standalone injection. Practices offering Mounjaro are expected to provide what is described as wraparound care: dietary advice, physical activity support, and behavioural input delivered alongside the medicine, not instead of it. This is the direct link back to the prevention agenda’s founding logic — that sustainable change in a population’s metabolic health depends on combining any pharmacological tool with the structured diet and activity support that screening and prevention programmes already exist to deliver. A prescription issued without that supporting structure is not what the NHS pathway was designed to provide.
The Cost Gap Between NHS and Private Access
For eligible patients, an NHS prescription costs the standard NHS prescription charge, a small fraction of the private market price. Outside NHS eligibility, private prescribing is available but substantially more expensive: private pricing for these medicines commonly runs from around £100 to £350 a month depending on the drug, dose strength and provider, often before consultation or delivery fees are added. That gap is the practical reason NHS eligibility criteria attract so much public attention — for anyone who falls just outside the current BMI-and-comorbidity threshold, the private route remains open, but at a cost that puts it well beyond many household budgets.
Reading the Rules as Part of the Wider Prevention Picture
GLP-1 prescribing does not exist in isolation from the rest of the metabolic screening agenda. The comorbidities that determine eligibility — raised blood pressure, high cholesterol, type 2 diabetes — are precisely the measures that population screening programmes are built to catch. Whether someone reaches the eligibility threshold for a weight-loss injection is, in practice, downstream of whether their blood pressure, cholesterol and glucose have already been checked and recorded. Read that way, the eligibility ladder is less a standalone drug policy than a visible marker of how metabolic screening and treatment access are meant to work together across a phased, capacity-limited rollout.